Centogene, a provider of data-driven answers in rare and neurodegenerative diseases, has extended its partnership with Takeda to diagnose patients with lysosomal storage disorders.

Under the renewed one-year partnership agreement, Centogene says it will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for lysosomal storage disorders, including Fabry disease, Gaucher disease, and Hunter syndrome, according to the organizations.

“We are excited to extend our partnership with Takeda to accelerate diagnosis and increase access to life-saving therapeutics for patients globally,” says Ian Rentsch, Centogene chief commercial officer and general manager – Pharma. “Leveraging our targeted diagnostic portfolio, network of over 30,000 active physicians, and the CENTOGENE Biodatabank driving novel insights, we are uniquely positioned to deliver substantial value to our pharma partners throughout every stage of the development pipeline. This collaboration continues to play a vital role in the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, brings life-changing answers to underserved patient communities.”

A key asset to the partnership is the Centogene Biodatabank, which currently contains approximately 700,000 patients representing over 120 highly diverse countries, more than 70% of whom are of non-European descent, including a large share of pediatric cases, the company says. By integrating multiomic and multi-ethnic data, the Centogene Biodatabank aims to provide a holistic view to enable accurate diagnosis and guide clinical actions.

In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from rare genetic diseases. Last year, the contract was extended until March 2023.